Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi- center trial by the Austrian Working Group For Medical Tumor Therapy
暂无分享,去创建一个
R. Greil | H. Hausmaninger | M. Fridrik | I. Simonitsch | M. Hudec | M. Neubauer | O. Krieger | B. Fazeny | J. Pont | T. Radaszkiewicz | J. Klocker | P. Oppitz | M. Stöger | W. Helm | M. A. Fridrik
[1] H. Hausmaninger,et al. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Murata,et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non‐Hodgkin's lymphoma , 1994, Cancer.
[3] H Stein,et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.
[4] B. Coiffier,et al. Possible toxicity with the association of G-CSF and bleomycin , 1994, The Lancet.
[5] M. Engelhard,et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas [see comments] , 1993 .
[6] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[7] J. von Pawel,et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. , 1993, European journal of cancer.
[8] M. Engelhard,et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas. , 1993, Blood.
[9] M. Shipp. Prognostic factors in non-Hodgkin's lymphoma. , 1992, Current opinion in oncology.
[10] J. Radford,et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. , 1992, Blood.
[11] M. Kris,et al. Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer , 1991 .
[12] E. Jaffe,et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] W. Hryniuk,et al. The calculation of received dose intensity. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Pinkus,et al. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R Storb,et al. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis of normal dogs and on hematopoietic recovery after otherwise lethal total body irradiation. , 1989, Blood.
[16] B. Coiffier,et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Green,et al. EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPY , 1988, The Lancet.
[18] E. Gehan,et al. Reporting outcomes in Hodgkin's disease and lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] K. Zsebo,et al. In vivo stimulation of granulopoiesis by recombinant human granulocyte colony-stimulating factor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[20] J. Gabrilove,et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. , 1986, Science.
[21] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[22] Prof. Dr. Dr. h.c. mult. Karl Lennert,et al. Histopathologie der Non-Hodgkin-Lymphome , 1981, Springer Berlin Heidelberg.
[23] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[24] Y. S. Sathe,et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.